An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504273-21-00

Enrollment

Registered

2023-09-04

Start date

2023-10-31

Completion date

Unknown

Last updated

2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

A participant is considered to have completed the study if he or she is followed until disease progression, withdrawal of consent, loss to follow up, death or end of study.

Interventions

DRUGELRANATAMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
A participant is considered to have completed the study if he or she is followed until disease progression, withdrawal of consent, loss to follow up, death or end of study.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026